WO2006003013B1 - NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1 - Google Patents
NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1Info
- Publication number
- WO2006003013B1 WO2006003013B1 PCT/EP2005/007315 EP2005007315W WO2006003013B1 WO 2006003013 B1 WO2006003013 B1 WO 2006003013B1 EP 2005007315 W EP2005007315 W EP 2005007315W WO 2006003013 B1 WO2006003013 B1 WO 2006003013B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxy
- estra
- trien
- triene
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007518558A JP2008504338A (ja) | 2004-07-02 | 2005-07-04 | 17β−ヒドロキシステロイドデヒドロゲナーゼタイプ1のインヒビターとしての新規2−置換されたエストラ−1,3,5(10)−トリエン−17−オン |
EP05767936A EP1771461A2 (de) | 2004-07-02 | 2005-07-04 | Neue 2-substituierte estra-1,3,5(10)-trien-17-one als inhibitoren der 17beta-hydroxy-steroiddehydrogenase typ 1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004032674A DE102004032674A1 (de) | 2004-07-02 | 2004-07-02 | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
DE102004032674.6 | 2004-07-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006003013A2 WO2006003013A2 (de) | 2006-01-12 |
WO2006003013A3 WO2006003013A3 (de) | 2006-06-22 |
WO2006003013B1 true WO2006003013B1 (de) | 2006-08-31 |
Family
ID=35207898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/007315 WO2006003013A2 (de) | 2004-07-02 | 2005-07-04 | NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1771461A2 (de) |
JP (1) | JP2008504338A (de) |
DE (1) | DE102004032674A1 (de) |
WO (1) | WO2006003013A2 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004032673A1 (de) * | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 |
US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
EP3013847B1 (de) | 2013-06-25 | 2019-08-21 | Forendo Pharma Ltd | Therapeutisch aktive estratrienthiazolderivate als inhibitoren von 17.beta.-hydroxy-steroiddehydrogenase typ 1 |
CN105518016B (zh) | 2013-06-25 | 2020-10-23 | 佛恩多制药有限公司 | 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物 |
WO2014207310A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
WO2016102775A1 (en) | 2014-12-23 | 2016-06-30 | Forendo Pharma Ltd | PRODRUGS OF 17β-HSD1 -INHIBITORS |
WO2016102776A1 (en) | 2014-12-23 | 2016-06-30 | Forendo Pharma Ltd | Prodrugs of 17.beta.-hsd1 -inhibitors |
CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
PL3634975T3 (pl) | 2017-06-08 | 2024-07-01 | Organon R&D Finland Ltd | 17-oksymy 15.beta.-[3-propanamido]-podstawionych estra-1,3,5(10)-trien-17-onów do stosowania w hamowaniu aktywności 17.beta.-dehydrogenaz hydroksysteroidowych |
BR112021010598A2 (pt) | 2018-12-05 | 2021-08-24 | Forendo Pharma Ltd | Compostos, método para preparação de um composto e composição farmacêutica |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB857081A (en) * | 1956-05-29 | 1960-12-29 | Syntex Sa | Cyclopentanophenanthrene derivatives and process for the production thereof |
US3562260A (en) * | 1965-08-23 | 1971-02-09 | Ormonoterapia Richter Spa | 2-carbonyl-estratrienes and method of their preparation |
BR9908592A (pt) * | 1998-03-11 | 2001-04-24 | Endorech Inc | Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit |
EP1102582A2 (de) * | 1998-08-07 | 2001-05-30 | Endorecherche Inc. | Typ 3 3alpha-hydroxysteroid dehydrogenase hemmer |
EP1237902B1 (de) * | 1999-12-13 | 2005-11-02 | Sterix Limited | Halogenierte sulphamat-, phosphonat-, thiophosphonat-, sulphonat- und sulphonamid- verbindungen als inhibitoren von steroidsulfatase |
US6518261B2 (en) * | 2000-03-17 | 2003-02-11 | Oncology Sciences Corporation | Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers |
AU2001279955A1 (en) * | 2000-08-18 | 2002-03-04 | Sterix Limited | 2-substituted estradiol derivative for inhibiting superoxid dismutase |
GB0025788D0 (en) * | 2000-10-20 | 2000-12-06 | Sterix Ltd | Use |
ES2287184T3 (es) * | 2000-11-03 | 2007-12-16 | Washington University | Estructuras aromaticas modificadas con sustituyentes hidroxi-, que tienen actividad citoprotectora. |
WO2002062347A1 (en) * | 2001-02-05 | 2002-08-15 | Oncology Sciences Corporation | Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis |
CN1867577A (zh) * | 2003-05-13 | 2006-11-22 | 克里普托法玛有限公司 | 雌三烯衍生物 |
US7498322B2 (en) * | 2004-03-12 | 2009-03-03 | Entremed, Inc. | Antiangiogenic agents |
-
2004
- 2004-07-02 DE DE102004032674A patent/DE102004032674A1/de not_active Ceased
-
2005
- 2005-07-04 WO PCT/EP2005/007315 patent/WO2006003013A2/de active Application Filing
- 2005-07-04 EP EP05767936A patent/EP1771461A2/de not_active Withdrawn
- 2005-07-04 JP JP2007518558A patent/JP2008504338A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE102004032674A1 (de) | 2006-01-26 |
JP2008504338A (ja) | 2008-02-14 |
WO2006003013A3 (de) | 2006-06-22 |
WO2006003013A2 (de) | 2006-01-12 |
EP1771461A2 (de) | 2007-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69232590T2 (de) | Sex steroide inhibitonen | |
WO2006003013B1 (de) | NEUE 2-SUBSTITUIERTE ESTRA-1,3,5(10)-TRIEN-17-ONE ALS INHIBITOREN DER 17β-HYDROXYSTEROIDDEHYDROGENASE TYP 1 | |
DE60025817T2 (de) | Ent-steroide als selektiv wirksame estrogene | |
EP1272504B1 (de) | 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene | |
CH641679A5 (de) | Mittel zur prophylaxe und therapie der prostatahyperplasie auf basis von antioestrogenen und antigonadotrop wirkenden antiandrogenen. | |
EP2456781A2 (de) | 17-hydroxy-17-pentafluorethyl-estra-4,9 (10)-dien-11-acyloxyalkylenphenyl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten | |
WO1998033506A1 (en) | Androgen synthesis inhibitors | |
HRP20100230T1 (hr) | NOVI 2-SUPSTITUIRANI D-HOMO-ESTRA-1,3,5(10)-TRIENI KAO INHIBITORI 17ß-HIDROKSISTEROIDNE DEHIDROGENAZE TIPA 1 | |
CH648211A5 (de) | Mittel zur prophylaxe und therapie der prostatahyperplasie. | |
WO2007002862A3 (en) | Compositions and methods for treatment of cycle-related symptoms | |
DE10159217A1 (de) | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate | |
CN1450900A (zh) | 抗肿瘤剂 | |
EP1144431B1 (de) | 16-hydroxyestratriene als selektiv wirksame estrogene | |
EP1599493B1 (de) | Antitumor wirksame 2-substituierte estra-1,3,5(10)-trien-3-yl sulfamate | |
Kochakian | HISTOCHEMICAL STUDY OF ‘ALKALINE’PHOSPHATASE THE KIDNEY OF THE CASTRATED MOUSE AFTER STIMULATION WITH VARIOUS ANDROGENS | |
ZA201908404B (en) | 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases | |
JP5061109B2 (ja) | 抗性腺刺激剤としての9,11−コルテキソロンのC3−C1017α−エステル類 | |
MXPA05012841A (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. | |
DE3339295A1 (de) | 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung | |
EP1747230A1 (de) | Aminosulfonyl- oder aminosulfonylamino-substituierte phenyl-ester als estradiol-prodrugs | |
Celasco et al. | Pharmacological profile of 9, 11-dehydrocortexolone 17α-butyrate (CB-03-04), a new androgen antagonist with antigonadotropic activity | |
EP1594884B1 (de) | Antitumor wirksame 2-substituierte 18a-homoestra-1,3,5(10)-trien-3-yl sulfamate | |
GB0108865D0 (en) | The use of agents to cause intermittent lowering of levels of cortisol and other adrenalhormones as treatment of clinical conditions associated with changes | |
EP1594886A1 (de) | Antitumor wirksame 2-substituierte d-homoestra-1,3,5(10)-trien-3-yl sulfamate | |
JP2007510661A5 (de) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005767936 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007518558 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005767936 Country of ref document: EP |